News

Archives
1 Oct 2012

Findings: Aspirin selectively benefits CRC patients who harbour the PIK3CA mutation

The NEJM has published findings that aspirin selectively benefits CRC patients who harbour the PIK3CA mutation.  The HR for CRC specific survival was an impressive 0.18 (CI 0.06-0.61) and these findings will need to be validated in our ASCOLT study.